PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective
Journal Title: Advances in Hygiene and Experimental Medicine - Year 2016, Vol 70, Issue
Abstract
Current cancer therapies are based mainly on the use of compounds that cause DNA damage. Unfortunately, even the combination therapies do not give rewarding effects, due to the high efficiency of DNA damage repair mechanisms in tumor cells. Therefore, the present studies should be focused on proteins that are involved in DNA repair systems. Poly(ADP-ribose) polymerase-1 is an example of a protein commonly known as an enzyme that plays a role in the detection of DNA damage and repair. Activation of PARP1 in response to DNA damage leads to poly-ADP-ribosylation of proteins contributing to DNA repair systems, therefore facilitating the maintenance of genome stability. On the other hand, inhibition of PARP1 enzyme results in the accumulation of DNA damage, which in turn contributes to cell death. Studies on inhibitors of PARP1 are still ongoing, and some of them are currently in the third phase of clinical trials. To date, only one representative of the PARP1 inhibitors, called olaparib, has been approved for anti-cancer therapy in the EU and the USA. Moreover, a growing body of evidence indicates a role of this protein in various intracellular processes such as bioenergetics, proliferation, regulation of gene expression, cell death as well as immunoregulation. A number of different intracellular processes regulated by PARP1 give rise to potential wider use of PARP1 inhibitors in treatment of other diseases, including immune or autoimmune disorders.
Authors and Affiliations
Ewelina Wiśnik, Marcin Ryksa, Maria Koter-Michalak
Keywords
Related Articles
- EP ID EP220760
- DOI -
- Views 154
- Downloads 0
Transportery błonowe ABCC – budowa, funkcja i znaczenie w mechanizmach wytwarzania oporności wielolekowej w komórkach nowotworów złośliwych
Oporność na leki cytotoksyczne jest obecnie poważnym problemem leczenia systemowego nowotworów. Jednym z mechanizmów oporności, oprócz inaktywacji leku w komórkach docelowych, zmiany punktu uchwytu dla leku, nasilenia pr...
Anti-oxidative and anti-inflammatory effects of lipoic acid in rat liver
Introduction: Lipopolysaccharide (LPS) is a key inflammatory component of Gram-negative bacteria, which after entering the systemic circulation contributes to the development of septic hepatic failure.Aim: The aim of thi...
Overuse of proton pump inhibitors and its consequences
Direct inhibition of H+ ion excretion to the gastric lumen makes proton pump inhibitors (PPI) the most effective drugs against gastric acid-related diseases. Over recent years usage of proton pump inhibitors has increase...
„Błędne koła” glejaków: unaczynienie i inwazyjność
Glejak wielopostaciowy to szczególnie złośliwa postać nowotworu glejopochodnego. Nowotwór ten stanowi około 70% wszystkich zdiagnozowanych nowotworów mózgu. Niestety, średni czas przeżycia chorych na glejaki złośliwe nie...
Dysfunkcje lizosomów a choroby neurodegeneracyjne
Recent data advocate for the implication of lysosomes in the development of programmed cell death. Lysosomal dysfunction decreased the efficiency of autophagosome/lysosome fusion that leads to vacuolation of cells. Autop...